Last updated: April 1, 2025
Sponsor: Universidade Federal Fluminense
Overall Status: Active - Recruiting
Phase
N/A
Condition
Inflammation
Vascular Diseases
Williams Syndrome
Treatment
Placebo
Royal Jelly
Clinical Study ID
NCT06917131
Denise Mafra21
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- patients using one to three antihypertensive medications, undergoing regularfollow-up at the HUAP Medical Clinic for more than 6 months and without the need forchanges in medication doses in the last 3 months.
Exclusion
Exclusion Criteria:
- Patients with autoimmune and infectious diseases, diabetes, chronic kidney disease,liver disease, cancer and AIDS will be excluded; pregnant women; those usingcatabolic drugs or antibiotics; use of antioxidant vitamin supplements, prebiotics,probiotics, symbiotics, habitual intake of royal jelly, and who are allergic tocornstarch or report having an allergy to bee stings will also be excluded. Patientswith acute myocardial infarction (AMI) and/or stroke (CVA) in the last 6 months willalso be excluded; with HAS stages 2 or 3.
Study Design
Total Participants: 34
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
September 18, 2024
Estimated Completion Date:
December 20, 2025
Study Description
Connect with a study center
Denise Mafra
Rio de janeiro, 22260050
BrazilActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.